AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
Phase 3positiveEpkinlyPolivyPositive
AI Analysis
Summary
AbbVie and Genmab announced positive Phase 3 data for Epkinly, a T-cell engager, in first-line DLBCL, positioning it as a competitive alternative to Roche's Polivy in the lymphoma market.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Epkinly passed late-stage trial in first-line DLBCL
Importance:8/10
Sentiment:
0.85
Phase 3 trialoncologyT-cell engagerlymphomamarket competition
Read the original article
Published by Endpoints News on October 6, 2026 11:05 AM